Molecular Partners AG
MOLN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745114
No open-market purchases or sales by Molecular Partners AG insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Holders of 5% or more of MOLN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Molecular Partners AG, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 13G | 10.60%4.28M shares | New | May 2, 20251 filing | May 2, 2025 | SEC |
| UBS Asset Management Americas Inc | 13G | 5.80%2.14M shares | New | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Molecular Partners AG, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jul 17, 20254:06 PM ET | UBS Asset Management Americas Inc | 13G | 5.80%2.14M shares | New | Sep 30, 2024 | SEC |
| May 2, 20255:14 PM ET | Suvretta Capital Management, LLCand 2 others | 13G | 10.60%4.28M shares | New | Jun 15, 2021 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Molecular Partners AG shares.
No Form 144 notices for Molecular Partners AG are on file.